Biogen Financial Statements (BIIB)
|
|
|
|
Report date
|
|
|
06.02.2020 |
03.02.2021 |
03.02.2022 |
15.02.2023 |
31.12.2023 |
|
30.10.2024 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
14 378 |
13 445 |
10 982 |
10 173 |
9 836 |
|
9 405 |
|
Operating Income, bln rub |
|
|
7 043 |
4 550 |
2 841 |
2 320 |
1 297 |
|
1 940 |
|
EBITDA, bln rub |
? |
|
7 778 |
5 730 |
2 486 |
4 357 |
2 377 |
|
2 895 |
|
Net profit, bln rub |
? |
|
5 889 |
4 001 |
1 556 |
3 047 |
1 161 |
|
1 615 |
|
|
OCF, bln rub |
? |
|
7 079 |
4 230 |
3 640 |
1 384 |
1 547 |
|
2 127 |
|
CAPEX, bln rub |
? |
|
669.5 |
551.8 |
294.9 |
243.2 |
311.4 |
|
506.6 |
|
FCF, bln rub |
? |
|
6 409 |
3 678 |
3 345 |
1 141 |
1 236 |
|
2 176 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
5 387 |
7 193 |
6 064 |
4 993 |
5 205 |
|
4 647 |
|
Cost of production, bln rub |
|
|
1 955 |
1 805 |
2 110 |
2 278 |
2 533 |
|
2 652 |
|
R&D, bln rub |
|
|
2 281 |
3 991 |
2 501 |
2 231 |
2 462 |
|
1 939 |
|
Interest expenses, bln rub |
|
|
187.4 |
222.5 |
253.6 |
246.6 |
246.9 |
|
261.8 |
|
|
Assets, bln rub |
|
|
27 234 |
24 619 |
23 877 |
24 554 |
26 845 |
|
28 313 |
|
Net Assets, bln rub |
? |
|
13 339 |
10 686 |
10 960 |
13 388 |
14 799 |
|
16 359 |
|
Debt, bln rub |
|
|
6 368 |
7 828 |
7 604 |
6 614 |
7 338 |
|
6 651 |
|
Cash, bln rub |
|
|
4 476 |
2 610 |
3 803 |
4 893 |
1 050 |
|
1 699 |
|
Net debt, bln rub |
|
|
1 892 |
5 218 |
3 801 |
1 721 |
6 288 |
|
4 952 |
|
|
Ordinary share price, rub |
|
|
296.7 |
244.9 |
239.9 |
276.9 |
258.8 |
|
242.7 |
|
Number of ordinary shares, mln |
|
|
187.1 |
160.9 |
149.1 |
145.3 |
144.7 |
|
145.7 |
|
|
Market cap, bln rub |
|
|
55 518 |
39 398 |
35 772 |
40 236 |
37 444 |
|
35 367 |
|
EV, bln rub |
? |
|
57 410 |
44 616 |
39 573 |
41 958 |
43 732 |
|
40 319 |
|
Book value, bln rub |
|
|
4 054 |
1 840 |
2 977 |
5 789 |
217 |
|
68 |
|
|
EPS, rub |
? |
|
31.5 |
24.9 |
10.4 |
21.0 |
8.02 |
|
11.1 |
|
FCF/share, rub |
|
|
34.3 |
22.9 |
22.4 |
7.85 |
8.54 |
|
14.9 |
|
BV/share, rub |
|
|
21.7 |
11.4 |
20.0 |
39.8 |
1.50 |
|
0.46 |
|
|
EBITDA margin, % |
? |
|
54.1% |
42.6% |
22.6% |
42.8% |
24.2% |
|
30.8% |
|
Net margin, % |
? |
|
41.0% |
29.8% |
14.2% |
29.9% |
11.8% |
|
17.2% |
|
FCF yield, % |
? |
|
11.5% |
9.34% |
9.35% |
2.84% |
3.30% |
|
6.15% |
|
ROE, % |
? |
|
44.1% |
37.4% |
14.2% |
22.8% |
7.85% |
|
9.87% |
|
ROA, % |
? |
|
21.6% |
16.3% |
6.52% |
12.4% |
4.33% |
|
5.70% |
|
|
P/E |
? |
|
9.43 |
9.85 |
23.0 |
13.2 |
32.2 |
|
21.9 |
|
P/FCF |
|
|
8.66 |
10.7 |
10.7 |
35.3 |
30.3 |
|
16.3 |
|
P/S |
? |
|
3.86 |
2.93 |
3.26 |
3.96 |
3.81 |
|
3.76 |
|
P/BV |
? |
|
13.7 |
21.4 |
12.0 |
6.95 |
172.4 |
|
523.2 |
|
EV/EBITDA |
? |
|
7.38 |
7.79 |
15.9 |
9.63 |
18.4 |
|
13.9 |
|
Debt/EBITDA |
|
|
0.24 |
0.91 |
1.53 |
0.40 |
2.65 |
|
1.71 |
|
|
R&D/CAPEX, % |
|
|
340.6% |
723.3% |
848.2% |
917.4% |
790.6% |
|
382.8% |
|
|
CAPEX/Revenue, % |
|
|
4.66% |
4.10% |
2.69% |
2.39% |
3.17% |
|
5.39% |
|
| Biogen shareholders |
